Position in AZN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$171,606
+$139,657 QoQ
Shares Held
905
+458.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,207
of 1,462 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AZN Over Time
Shares Held
Position Value (USD)
Derivatives in AZN
reported options exposure · as of Jun 30, 2026CallValue
$549,898
CallShares
2,900
PutValue
$549,898
PutShares
2,900
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Capula Management Ltd holds $156,174,841 across 9 Drug Manufacturers - General names. AZN ranks #7 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMGN |
Amgen Inc
|
300,064 | $108,659,175 | |
| 2 | OGN |
Organon & Co.
|
3,049,207 | $41,286,262 | |
| 3 | PFE |
Pfizer Inc
|
170,245 | $4,099,499 | |
| 4 | ABBV |
AbbVie Inc.
|
3,168 | $797,195 | |
| 5 | LLY |
ELI LILLY & Co
|
596 | $714,860 | |
| 6 | JNJ |
Johnson & Johnson
|
875 | $222,222 | |
| 7 | AZN |
Astrazeneca PLC
This page
|
905 | $171,606 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
1,147 | $144,911 |
All Filings in AZN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $549,898 | 2,900 | Call | Defined | 2026-08-14 | |
| 2026-06-30 | $171,606 | 905 | Shares | Defined | 2026-08-14 | |
| 2026-06-30 | $549,898 | 2,900 | Put | Defined | 2026-08-14 | |
| 2026-03-31 | $571,938 | 2,900 | Put | Defined | 2026-05-14 | |
| 2026-03-31 | $571,938 | 2,900 | Call | Defined | 2026-05-14 | |
| 2026-03-31 | $31,949 | 162 | Shares | Defined | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||